Cytogenetic effects of dacarbazine on mouse bone marrow cells in vivo.

The mutagenicity of dacarbazine was assayed in an in vivo test utilizing mouse bone marrow cells. The dose rates used in the experiments were computed according to the standard surface area of the mouse and were proportional to the human dose rate. These were 0.27, 0.44 and 0.60 mg/30 g body weight, each given twice daily at an interval of not less than 6 h. The duration of drug treatment was 24, 48 and 72 h. This alkylating agent proved to be mitodepressive and produced a 3-fold reduction in the mitotic index. The drug also induced chromosome anomalies mainly in the form of chromatid gaps and breaks. These anomalies were proportional to dose rate and duration of drug treatment.